Taisho Pharmaceutical Pabron Gold A (Granules) unlicensed product:, product is labelled to contain dihydrocodeine phosphate that is listed on Schedule I of the CDSA
Brand(s)
Summary
Consult your health care professional if you have any health concerns.
Affected products
Brand Product Name |
Product Name |
Market Authorization |
Dosage Form |
Strength |
Lot |
|---|---|---|---|---|---|
Taisho Pharmaceutical Pabron Gold A |
Taisho Pharmaceutical Pabron Gold A |
No market authorization |
Granules |
Guaifenesin 60 mg, Dihydrocodeine phosophate 8 mg, dl-Methylephedrine Hydrochloride 20 mg, Acetaminophen 300 mg, Chlorpheniramine Maleate 2.5 mg, Anhydrous Caffeine 25 mg, Riboflavin 4 mg |
All |
Issue
Product sold without market authorization (DIN) in Canada. Product is labelled to contain dihydrocodeine phosphate that is listed on Schedule I of the Controlled Drugs and Substances Act. Product is labelled to contain guaifenesin, dl-methylephedrine hydrochloride, acetaminophen, chlorpheniramine maleate and caffeine that may pose a risk to health.
What you should do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Background
Depth of recall: Retailers
Details
Roope International Trading Ltd.
118-21300 Gordon Way,
Richmond, BC
V6W 1J8
Get notified
Receive notifications for new and updated recalls and alerts by category.